Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRISď (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). Source
No articles found.
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Cerus Corporation is dedicated solely to safeguarding the worldâs blood supply a...
Cerus Corporation is dedicated solely to safegu...
Abeona Therapeutics is focused on developing and delivering gene therapy products ...
Abeona Therapeutics is focused on developing an...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.